Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Clinical trial NCT02301364 · COMPLETED

Trial details

NCT number: NCT02301364
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma Primary Central Nervous System Lymphoma Recurrent/Refractory Secondary Central Nervous System Lymphoma

Start date: 2014-11-20
Primary completion: 2016-10-11
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.